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The Journal of Immunology
Upstream Position of Proline Defines Peptide–HLA Class I
Repertoire Formation and CD8+ T Cell Responses
Ayumi Hongo,* Takayuki Kanaseki,* Serina Tokita,* Vitaly Kochin,† Sho Miyamoto,‡
Yuiko Hashino,* Amy Codd,x Noriko Kawai,* Munehide Nakatsugawa,*
Yoshihiko Hirohashi,* Noriyuki Sato,* and Toshihiko Torigoe*
Cytotoxic CD8+ T lymphocytes (CTLs) recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring
pathological conditions such as cancer. Difficulty in predicting HLA class I ligands is attributed to the complexity of the Ag
processing pathway across the cytosol and the endoplasmic reticulum. By means of HLA ligandome analysis using mass spec-
trometry, we collected natural HLA class I ligands on a large scale and analyzed the source-protein sequences flanking the ligands.
This comprehensive analysis revealed that the frequency of proline at amino acid positions 1–3 upstream of the ligands was
selectively decreased. The depleted proline signature was the strongest among all the upstream and downstream profiles. Exper-
iments using live cells demonstrated that the presence of proline at upstream positions 1–3 attenuated CTL responses against a
model epitope. Other experiments, in which N-terminal–flanking Ag precursors were confined in the endoplasmic reticulum,
demonstrated an inability to remove upstream prolines regardless of their positions, suggesting a need for synergistic action across
cellular compartments for making the proline signature. Our results highlight, to our knowledge, a unique role and position of
proline for inhibiting downstream epitope presentation, which provides a rule for defining natural peptide–HLA class I repertoire
formation and CTL responses. The Journal of Immunology, 2019, 202: 000–000.
C
ytotoxic CD8+ T lymphocytes (CTLs) recognize peptides
presented by HLA molecules on cell surfaces, monitoring
cellular abnormalities such as viral infection or tumor
transformation. Ag processing begins in the cytosol, where endog-
enous proteins are digested by the proteasomes and other peptidases
(1–4). Generated peptide precursors of protein fragments are then
transported into the endoplasmic reticulum (ER) through the TAP,
where the aminopeptidase ERAAP (ERAP1) customizes the pep-
tides and peptide–HLA class I (pHLA I) complexes are formed
(5–7). These pHLA I complexes are sorted onto a surface and
subsequently serve as targets of CTL recognition. Thus, HLA class
I peptide presentation is a selective process comprising multiple
steps across distinct cellular compartments.
Accurate prediction of CTL epitopes presented by HLA class I
molecules is an urgent issue for therapeutic purposes. Cancer
patients’ T cells recognize neoantigens that arise from gene mu-
tations (8); however, it is currently challenging to predict those
epitopes from hundreds or thousands of gene mutations (9). The
difficulty of accurate prediction is mostly due to the complexity of
Ag processing. Although attempts to predict enzymatic properties
of the proteasomes or TAP transport have been made (10, 11),
many of the currently used algorithms focus on the affinity or
stability between ligands and HLA class I molecules (12–15). This
leaves out the intracellular mechanisms by which peptides are
selected from the vast number of candidate protein fragments.
Meanwhile, recent advances in proteomics have revealed a land-
scape of naturally presented HLA class I ligands on a large scale
(16–19). The sequences detected by HLA ligandome analysis are
the “footprints” of the Ag processing machinery, representing the
intracellular selection process.
In this study, we isolated naturally presented HLA ligands from
tumor cells and searched the source-protein sequences flanking the
ligands for the footprints of Ag processing. To maintain natural
presentation signatures, if any, we leveraged affinity Abs against
specific HLA class I alleles and avoided the conventional
deconvolution process of assigning the mixture of peptides isolated
from multiple HLA alleles into their cognate alleles using algo-
rithms (20). Our results uncovered an upstream signature that was
shared across different HLA class I types. The frequency of pro-
line located at amino acid positions 1–3 upstream decreased and
was an unfavorable signature for HLA presentation, suggesting
that the presence of a preceding proline inhibited HLA class I
presentation of downstream epitopes. This finding was validated
by model experiments using live cells that demonstrated the se-
quential action of processing machinery across cellular compart-
ments in making the proline signature. Our results demonstrate
how proline at upstream positions influences Ag processing and
surface pHLA I repertoire formation. Integration of this rule could
reduce the false positive rate and thereby improve the accuracy of
epitope prediction.
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The histological origins and HLA genotypes of the human tumor cell lines
are as follows: MKN45 (Japanese Collection of Research Bioresources
Cell Bank), gastric cancer, HLA-A*24:02, B*67:02, B*52:01, and
C*12:02; KHM2B (a gift from Dr. T. Sonoki, Wakayama Medical Uni-
versity), Burkitt lymphoma, HLA-A*24:02, B*52:01, and C*12:02;
SW480 (American Type Culture Collection [ATCC]), colon cancer,
HLA-A*24:02, A*02:01, B*07:02, B*15:18, and C*07:04; and DU145
(ATCC), prostate cancer, HLA-A*33:03, B*50:01, B*57:01, and C*06:02.
The HLA genotype of KHM2B was determined using a commercially
available service (LSI Medience), and the others were obtained from the
TRON Cell Line Portal (http://celllines.tron-mainz.de) (21). HEK293T cells
were purchased from the ATCC, and T2 cells expressing HLA-A24
(T2-A24) were a gift from Dr. K. Kuzushima (Aichi Cancer Center Re-
search Institute). 293T-A24 is a 293T clone stably expressing an HLA-A*24:02
gene construct and was established in our laboratory. A CTL clone specific to
IV9/HLA-A24 is described elsewhere (22).
Abs for HLA class I ligand isolation
Hybridomas for anti–HLA-A24 (C7709A2; a gift from Dr. P. G. Coulie,
Ludwig Institute for Cancer Research), anti–HLA-A02 (BB7.2; ATCC),
and pan–HLA class I (W6/32; ATCC) were cultured in Hybridoma-SFM
(Life Technologies) supplemented with 1% penicillin/streptomycin in
CELLine bioreactor flasks (Corning). Produced mAbs were condensed and
collected through a semipermeable membrane during cell culture.
HLA class I ligand elution
Cell lysates were prepared from ∼1.0 3 109 KHM2B, MKN45, SW480, and
DU145 cells with lysate buffer containing 0.6% CHAPS (Dojindo Molecular
Technologies) and 13 complete protease inhibitor (Roche) in PBS. The pHLA
I complexes were captured using affinity chromatography of either C7709A2,
BB7.2, or W6/32 Abs coupled to cyanogen bromide–activated Sepharose 4B
(GE Healthcare). The HLA ligands were eluted with 0.2% trifluoroacetic acid,
passed through a 10-kDa ultra-centrifugal filter (Millipore), condensed by
vacuum centrifugation, and desalted using C18 ZipTip (Millipore).
Liquid chromatography–tandem mass spectrometry analysis
This procedure has been previously described (19, 22). Samples were loaded
into a nanoflow liquid chromatograph (Easy-nLC 1000 system; Thermo
Fisher Scientific) online-coupled to an Orbitrap mass spectrometer equipped
with a nanospray ion source (Q-Exactive Plus; Thermo Fisher Scientific). We
used a 75 mm 3 20 cm capillary column with a particle size of 3 mm
(NTCC-360; Nikkyo Technos) and separated the samples with a linear
gradient ranging from 3 to 30% buffer B (100% acetonitrile and 0.1% formic
acid) at a flow rate of 300 nl/min for 80 min. In mass spectrometry (MS)
analysis, survey scan spectra were acquired at a resolution of 70,000 at 200
mass-to-charge ratio (m/z) with a target value of 3e6 ions ranging from 350
to 2000 m/z with charge states between 1+ and 4+. We applied a data-
dependent top 10 method that generates high-energy collision dissociation
fragments for the 10 most intense precursor ions per survey scan. Tandem
MS (MS/MS) resolution was 17,500 at 200 m/z with a target value of 1e5
ions. For database matching of the MS/MS spectra, we used both Sequest
HT (Thermo Fisher Scientific) and Mascot version 2.6 (Matrix Science)
algorithms embedded in the Proteome Discoverer 2.2 platform (Thermo
Fisher Scientific). The peak lists were searched against the Swiss-Prot human
databases with a tolerance of precursor ions at 10 ppm and fragment ions at
0.02 Da. We applied a false-discovery rate (FDR) of 0.01 as a stringent
threshold and removed known contaminant sequences.
Upstream and downstream profiles of HLA ligands
Up to 15 upstream and downstream amino acid residues adjoining all the
isolated 9–11-mer HLA ligands were derived from the Swiss-Prot database
(https://www.uniprot.org). Fold changes (FC) were calculated as follows:
FC = the number of a given amino acid at a given upstream (or down-
stream) position / the median number of that amino acid across upstream
positions 1–15 (or downstream positions 1–15). Frequency in the heat map
is shown as log2(FC).
DNA constructs
The ASB4 gene in SW480 was amplified using a pair of PCR primers
containing a FLAG tag (59-ATTAGGATCCATGGACGGCACCACTGCCC-39
and 59-AGATCTCGAGTTACTTATCGTCGTCATCCTTGTAATCATAAAT-
AATTCC-39) and inserted into pcDNA3.1 (Invitrogen). Single amino acid
substitution of residues preceding an IV9 epitope was carried out using site-




P.U3, 59-CATGGGCCTGCCCGAATATACCCTCCA-39 and 59-TCGG-
GCAGGCCCATGGTTCAACAGGAG-39; P.U4, 59-AACCATCCTGCTGCCC-
GAATATACCCT-39 and 59-GGCAGCAGGATGGTTCAACAGGAGCTG-39;
P.U5, 59-TTGAACCCTGGGGCTGCCCGAATATAC-39 and 59-AGCCCCA-
GGGTTCAACAGGAGCTGGTA-39; P.U6, 59-CTGTTGCCTCATGGGGCTG-
CCCGAATA-39 and 59-CCCATGAGGCAACAGGAGCTGGTAGCA-39;
N.U1, 59-GCTGCCAATATATACCCTCCACAGTTC-39 and 59-GTAT-
ATATTGGCAGCCCCATGGTTCAA-39; D.U2, 59-GGGCTGATCGAAT-
ATACCCTCCACAG-39 and 59-ATATTCGATCAGCCCCATGGTTCAACAG-
39; M.U2, 59-GGGCTATGCGAATATACCCTCCACAG-39 and 59-ATATTCG-
CATAGCCCCATGGTTCAACAG-39; V.U3, 59-CATGGGGTAGCCCGAATAT-
ACCCTCCA-39 and 59-TCGGGCTACCCCATGGTTCAACAGGAG-39; and
M.U3, 59-CATGGGATGGCCCGAATATACCCTCCA-39 and 59-TCGGGC-
CATCCCATGGTTCAACAGGAG-39. All the nucleotide substitutions
were verified with DNA sequencing. As for ER series constructs, an
ER-targeting signal sequence derived from the adenovirus E3/19K protein
(59-ATGAGGTACATGATCCTGGGCCTGCTGGCCCTGGCCGCCGTG-
TGCAGCGCCGCCGCCGCCATCGTGATGGAC-39), followed by a se-
quence encoding flanking residues (59-AACCATGGGGCTGCCCGA-39)
and the IV9 epitope coupled with a stop codon (59-ATATACCCT-
CCACAGTTCCATAAGGTGTAA-39) were cloned into pLenti-puro (Addgene).
Nucleotide substitutions of the flanking sequences were carried out using site-
directed mutagenesis with the following PCR primer pairs: ER.P.U1, 59-
GCTGCCCCTATATACCCTCCACAGTTC-39 and 59-GTATATAGGGGCAG-
CCCCATGGTTGTC-39; ER.P.U2, 59-GGGGCTCCTCGAATATACCCT-
CCACAG-39 and 59-TATTCGAGGAGCCCCATGGTTGTCCAT-39; ER.P.




and 59-AGCCCCAGGGTTGTCCATCACGATGGC-39; and ER.P.U6,
59-ATGGACCCTCATGGGGCTGCCCGAATA-39 and 59-CCCATGA-
GGGTCCATCACGATGGCGGC-39. All the nucleotide substitutions
were verified with DNA sequencing. Using the SignalP prediction
algorithm (http://www.cbs.dtu.dk/services/SignalP), we confirmed that
none of the inserted 5-aa flanking residues were cleaved by a signal
peptidase.
Western blot
Cells were lysed with a buffer containing 50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 5 mM EDTA, 1% NP40, and a protease inhibitor mixture
(Roche) for 30 min at 4˚C. Samples were separated by 12% SDS-PAGE,
transferred to PVDF membranes, and blocked with 5% milk in PBS for 1 h
at room temperature. Abs used for blotting were as follows: mouse anti-
Flag (1:2000), mouse anti–b-actin (1:5000), and HRP-conjugated goat
anti-mouse Ig (1:5000). Signals were detected using ECLWestern Blotting
Detection Reagents (GE Healthcare) and an Odyssey Fc imaging system
(LI-COR Biosciences).
IFN-g ELISPOT assay
IFN-g production by IV9-specific CTL clones was assessed using the
ELISPOT assay (human IFN-g ELISPOT set; BD Biosciences) according
to the manufacturer’s instructions. A total of 1–5 3 104 IV9-CTL clones
were incubated overnight with the equivalent number of target cells that
were either 293T-A24 cells transiently expressing one of a series of ASB4
Ag constructs, or T2-A24 cells stably expressing one of a series of ER-IV9
Ag constructs. The wells were incubated with biotinylated anti-human IFN-g
for 2 h at room temperature followed by an ELISPOT streptavidin–HRP Ab
for 1 h. Spots were visualized using the ELISPOT AEC Substrate Set (BD
Biosciences). For blocking the activity of the proteasomes, target cells were
preincubated with 0.02 mM carfilzomib (ApexBio Technology) or 0.02 mM
bortezomib (Selleck) for 5 h. For blocking TAP transportation, the ICP47
gene construct (a gift from Dr. N. Hirano, University of Toronto) was
transiently expressed in 293T-A24 cells along with ASB4 Ag constructs (23).
RT-PCR
Total RNA was isolated from T2-A24 cells expressing a panel of Ag
constructs using an RNeasy Mini Kit (QIAGEN) according to the manu-
facturer’s instructions. The synthesis of cDNA was performed on 2 mg of
total RNA by reverse transcription using the RevertAid RT Reverse
Transcription Kit (Thermo Fisher Scientific). RT-PCR mixtures were
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initially incubated at 94˚C for 2 min, followed by 35 cycles of denaturation
at 94˚C for 15 s, annealing at 60˚C for 30 s, and extension at 72˚C for 15 s.
Primer pairs were as follows: ER-IV9, 59-ATGAGGTACATGAT-
CCTGGG-39 and 59-CACCTTATGGAACTGTGGAG-39 (product size 117
bp); and G3PDH, 59-ACCACAGTCCATGCCATCAC-39 and 59-TCCAC-
CACCCTGTTGCTGTA-39 (product size 452 bp).
Results
HLA class I ligandome analysis demonstrates the profile of
naturally presented peptides
By means of HLA-A24– and -A02–reactive mAbs, as well as a
pan–HLA class I Ab, we directly captured peptides that were
naturally presented by corresponding HLA class I molecules from
a panel of tumor cell lines. The peptides were subsequently ana-
lyzed using MS and sequenced at a stringent FDR threshold of
0.01. The data included 591 and 381 HLA-A*24:02–bound unique
peptides from KHM2B and MKN45, respectively, 336 HLA-
A*02:01–bound unique peptides from SW480, and 1374 HLA
class I (A*33:03, B*50:01, B*57:01, and C*06:02)–bound unique
peptides from DU145 (Fig. 1A). Both HLA-A*24:02 and
-A*02:01 peptides were directly eluted from tumor cells
expressing multiple HLA class I alleles using HLA allele–specific
mAbs so as not to be influenced by potential biases yielded by a
conventional deconvolution process or manipulation such as arti-
ficial HLA gene engineering of host cells. To validate the speci-
ficity of the pipeline, we assessed both length profiles and amino
acid conservation of detected peptide sequences. Among the de-
tected peptides, 9-mer peptides were enriched and the known
HLA-binding anchor motifs were conserved at P2 and P9, both of
which suggested the successful isolation of HLA-bound peptides
minimizing contamination (if any) of peptides from other HLA
alleles (Fig. 1B, 1C).
The frequency of upstream proline is decreased in naturally
presented HLA class I ligands
Considering that the number of HLA class I molecules is limited,
they cannot afford to present every peptide fragment generated
inside a cell. In actuality, the number of the peptides simultaneously
presented on a cell surface could be 0.01% or less of the peptides
generated inside a cell (24). Endogenous Ag processing across the
cytosol and the ER precedes pHLA I formation in the ER, di-
gestion of source proteins, and selection of peptides appropriate
for HLA class I binding. To investigate footprints of Ag pro-
cessing in shaping the pHLA I repertoires in our data sets, we
reconstituted the source-protein sequences that had originally
surrounded the HLA ligands. Up to 15 aa residues upstream
(upstream positions 1–15) and downstream (downstream positions
1–15) of the 2450 nonredundant natural HLA ligands were re-
covered from the Swiss-Prot database and classified according to
HLA or cell type along with the 9–11-mer HLA ligands (Fig. 2A).
First, we compared the amino acid composition across the HLA
ligand and upstream and downstream sequences. The standard
composition in the human proteome registered in the Swiss-Prot
database served as a reference (Fig. 2B). The compositions of the
HLA class I ligands varied across HLA types, and each compo-
sition was different from the reference, mainly because of the
conservation of anchor motifs according to HLA types (Fig. 2C).
In contrast, the compositions of upstream and downstream se-
quences were uniformly consistent with the reference, which in-
dicated a lack of particular residues necessary for presentation
(Fig. 2D, 2E). Lack of variations across HLA types may also
suggest that Ag processing that removes these flanking extensions
is not particular between HLA types.
Because no remarkable changes in compositions were found,
we further investigated positional biases within upstream or
downstream residues (Fig. 3A, 3B). We found that positional
variations in most amino acid residues were modest, except for
proline. In the upstream profile, proline at upstream positions
1–3 was selectively depleted in a row; its frequency was reduced
to one half to one fourth of the other positions (Fig. 3A). This
unique signature was not limited to a certain sample or HLA type
but was uniformly observed across data sets we have tested
(Supplemental Fig. 1). In the cases of HLA-A24 (KHM2B and
FIGURE 1. HLA ligandome analysis and collection of HLA-A24, -A2, and other HLA class I natural ligands. (A) A schematic pipeline of HLA
ligandome analysis with cell names, affinity Abs, target HLA alleles, and the resulting numbers of identified nonredundant HLA ligands (FDR of 0.01). (B)
Length distribution of detected peptides. The x-axis, peptide lengths (amino acids); the y-axis, numbers of unique peptides. (C) Conventional logo sequence
analysis of 9-mer ligands (https://weblogo.berkeley.edu/logo.cgi).
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MKN45), HLA-A2 (SW480), and a mixture of class I (DU145)
ligands, the depletion of proline was concentrated at upstream
positions 1–3 but not found at upstream position 4 or more up-
stream positions (Fig. 3C). As for downstream profiles, we found
that arginine, histidine, and serine were slightly enriched at
downstream position 1. These signatures were consistent with a
recent report in which single HLA class I–expressing B721.221
cell lines were used that suggested their conservation across
different cell types and HLA alleles (Fig. 3B) (25).
Presence of proline at upstream positions 1–3 inhibits CTL
responses against the following epitope
Depletion of proline at upstream positions 1–3 yielded its posi-
tional bias in upstream flanking sequences, suggesting that the
FIGURE 2. Upstream and downstream profiles of HLA class I ligands. (A) Up to 15 upstream and downstream residues flanking outside of the 9–11-mer
naturally presented HLA class I ligands were recovered from the Swiss-Prot database (https://www.uniprot.org) and reconstituted according to their cell
types (HLA types). (B) A standard amino acid composition from the UniProtKB/Swiss-Prot data bank (percentage) (https://web.expasy.org/protscale/
pscale/A.A.Swiss-Prot.html, release 2013_04). (C–E) The amino acid composition (percentage) in 9–11-mer HLA ligands (C) and upstream (D) and
downstream (E) residues of the HLA ligands.
FIGURE 3. Positional biases of amino acids in upstream and downstream profiles. (A and B) Distribution of amino acids across upstream (A) and
downstream (B) positions. The heat maps indicate the frequency of a given residue at a given position relative to the other position, shown as log2(FC). FC
was calculated as follows: the number of a given amino acid at a given upstream (or downstream) position / the median number of that amino acid across
upstream positions 1–15 (or downstream positions 1–15). Enriched and depleted residues are indicated as red and blue, respectively. Shown is the summary
of KHM2B, MKN45, SW480, and DU145. Appended bar graphs indicate amino acid composition (percentage) in each data set. (C) Proline distribution in
upstream sequences (upstream positions 1–15) across samples that carried different sets of peptides from different HLA alleles.
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presence of proline had deleterious effects on Ag processing of the
following peptides. Because this hypothesis has not been tested, to
our knowledge, we prepared 293T-A24 cells expressing a panel of
ASB4 Ag constructs (Fig. 4A). ASB4 is a known cancer-specific
Ag containing an IV9 epitope that is naturally presented by HLA-
A24 of colon cancer cells (22). The original ASB4 protein harbors
proline at upstream position 15, but not at upstream positions
1–14, of the IV9 epitope. In each construct, the HLA-A24 ligand
(IV9) followed the wild-type (WT) or a panel of substituted se-
quences in which proline or other indicated residues were
substituted across upstream positions 1–6. The uniform protein
expression of each Ag construct was verified using a tag as a
surrogate marker (Fig. 4B). Any substitutions made no detectable
changes in total HLA-A24 expression levels on cell surfaces
(Supplemental Fig. 2A). The IV9-specific CTL clone readily
responded to the WT construct and produced IFN-g; however, the
presence of proline at upstream positions 1–3 selectively attenu-
ated the CTL responses down to 21–40% of WT (Fig. 4C). The
CTL responses were not disturbed by the presence of proline at
upstream positions 4–6. Likewise, the CTL responded well to the
epitopes following randomly substituted amino acids with charged
(aspartic acid), polar uncharged (asparagine), or hydrophobic
(methionine and valine) side chains.
Ag processing begins in the cytosol, where epitope precursors
are generated and subsequently transported into the ER through the
TAP. To clarify the cellular compartment responsible for the proline
signature, we took advantage of TAP and proteasome inhibitors.
Coexpression of a TAP inhibitor, HSV-derived ICP47, successfully
decreased total HLA class I expression levels of the host cells
without changing the level of Ag expression (Supplemental Fig.
2B, 2C) (23). As we expected, coexpression of ICP47 influenced
the CTL response, reducing IFN-g production down to a nearly
undetectable level (Fig. 4D). Moreover, treatment with two types
of proteasome inhibitors also reduced the CTL response (Fig. 4E).
These results suggested that proteasomal digestion and TAP
transportation were necessary for Ag processing in this setting.
Therefore, we found that the presence of proline at upstream
positions 1–3, but not other amino acids, selectively inhibited CTL
responses when an Ag protein was expressed in the cytosol and
endogenously processed.
Inability of Ag processing in the ER to remove
upstream prolines
C-terminal ends of HLA ligands are determined in the cytosol prior
to transportation into the ER, whereas N-terminal–flanking ex-
tensions of potential ligands are trimmed by the ER-resident
aminopeptidase ERAAP (ERAP1) (26–29). Therefore, the ER is
the final compartment for shaping the pHLA I repertoire on cell
surfaces, and processing defects in the ER lead directly to alter-
ations in T cell recognition (30). To investigate the link between
the Ag processing in the ER and generation of the proline sig-
nature, we modified a panel of Ag constructs to confine their Ag
expression within the ER. The series of constructs had an ER-
targeting signal sequence followed by N-terminal–flanking resi-
dues containing a proline at upstream positions 1–6, and the IV9
epitope was coupled with a stop codon at the C-terminal end
(Fig. 5A). Each construct was introduced into TAP-deficient T2-
A24, and we confirmed that the gene expression levels of all the
mutant Ags (ER.P.U1–ER.P.U6) were uniform and comparable to
the WT (ER.WT) (Fig. 5B). The IV9-specific CTL clone recog-
nized T2-A24–expressing ER.WT, suggesting the successful re-
moval of flanking residues in this setting; however, the IFN-g
production against any of the mutant Ags (ER.U1–U6) was sig-
nificantly decreased (Fig. 5C). This result indicated a deleterious
effect of upstream prolines on Ag processing in the ER, and in
sharp contrast to the cytosolic Ag series in Fig. 4, prolines at any
of the six upstream positions equally impaired the CTL responses.
Carfilzomib or bortezomib treatments did not influence the re-
sponse against ER.WT, suggesting that proteasomal digestion was
not involved in this setting (Fig. 5D). We did not observe a de-
crease in surface HLA-A24 expression levels of T2-A24–
expressing ER.U1–U6, presumably because the Ab used for flow
FIGURE 4. Presence of proline at upstream positions 1–3 selectively inhibits CTL responses against the following epitope. (A) A panel of ASB4 Ag
constructs. The WT construct contains an HLA-A24–restricted 9-mer CTL epitope (IV9) as well as a FLAG sequence. In a series of mutant ASB4
constructs, bold letters indicate the substitution at upstream positions. (B) Western blot of 293T-A24 expressing indicated ASB4 constructs. Shown is a
representative blot of three independent experiments. (C) IFN-g production of an IV9-specific CTL clone against 293T-A24 expressing indicated ASB4
constructs. (D and E) IFN-g production by the CTL clone against 293T-A24 expressing WT in the presence or absence of ICP47 expression (D) or in the
presence or absence of 20 nM carfilzomib or bortezomib (E). IFN-g spots in the ELISPOT assay are shown as mean 6 SEM (n = 3), and p values were
calculated using a two-tailed t test. **p , 0.01.
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cytometry was not specific to the IV9-presenting HLA-A24 but
widely reacted with any HLA-A24 molecules on cell surfaces
(Supplemental Fig. 3). Taken together, these results demonstrate
impaired ER processing for removing upstream prolines, which is
consistent with ERAAP’s enzymatic preference (26). In contrast
to processing beginning in the cytosol, proline at any of up to six
upstream positions inhibited HLA class I presentation of the fol-
lowing CTL epitope in the ER.
Discussion
A previous report using data sets from the SYFPEITHI database
suggested that conservation of motifs represents preferences of
proteasomal cleavage and TAP transportation in N-terminal–
flanking sequences of HLA class I ligands (31). In the current study,
we used peptide elution and large-scale liquid chromatography–
MS/MS sequencing to generate a collection of naturally presented
HLA class I ligands and reconstituted flanking sequences that
had been removed by Ag processing. These data revealed a unique
signature of pHLA I repertoire on cell surfaces showing that
proline at positions upstream positions 1–3 was selectively de-
pleted. Based on the experiments using live cells expressing a
model cancer Ag, we demonstrated that 1) the presence of proline
at upstream positions 1–6 equally inhibited Ag processing in the
ER, but 2) only proline at upstream positions 1–3 predominantly
inhibited the processing when the Ag constructs were expressed in
the cytosol. These results suggest an inability of the ER to remove
upstream prolines and that removal of proline occurs in the cytosol
prior to transportation into the ER. Substrate residues preferred for
tryptic digestion, such as lysine or arginine, were not enriched at
upstream position 1, supporting that many of the 9–11-mer HLA
class I ligands are not directly generated by proteasomal digestion
(Fig. 3A, Supplemental Fig. 1A). Thus, we reached a conclusion
that was different from that of a recent report, in which the authors
proposed a direct influence of proteasomal digestion in making
upstream profiles (25). Synergistic action of processing in the
cytosol generating N-terminal–flanking precursors, and subse-
quent processing in the ER shapes final pHLA I repertoires dis-
played on cell surfaces, leaving the proline signature at upstream
positions 1–3 in natural pHLA I repertoires.
It was of interest that natural pHLA I repertoires harbored such a
signature of a single amino acid at a particular upstream position.
Proline is a unique amino acid owing to its circular side chain that
confers resistance to trimming by the ER-resident amino peptidase
ERAAP (ERAP1) (26, 32). Because ERAAP, along with ERAP2,
is the aminopeptidase responsible for peptide trimming in the ER,
we consider the proline signature in pHLA I repertoires to mirror
its enzymatic preference. Because ERAAP stops trimming at an
amino acid preceding proline, leaving X-P-Xn peptides intact, the
initial notion proposed that the inability to remove proline leads to
an accumulation of X-P-Xn peptides displayed by particular MHC
class I alleles (33). In this study, our findings further demonstrate
that the enzymatic preference also leads to depletion of some
proline-less HLA ligands on display, influencing natural pHLA I
repertoires. As far as we have surveyed, this proline signature was
observed in multiple HLA class I alleles, including the prevalent
HLA-A*24:02 and -A*02:01 alleles, indicating that this at least
was not an event specific to a particular allele. Meanwhile, en-
richment at upstream position 1 was barely detectable in other
residues, including leucine and methionine, both of which are
indeed residues ERAAP prefers (34). Although this signature was
modest in our data sets, it may imply the presence of positive
substrate selection according to ERAAP preference.
The biological significance of the proline signature remains
unclear. It has been reported that a mutation from alanine to proline
at upstream position 1 of an HIV-Gag protein–derived HLA-B57
epitope impairs CTL recognition, and the mutant strain survives
immune pressure (35). Although there is little evidence, it is also
plausible that cancer cells make use of the proline signature for im-
mune escape. The proline signature possibly helps avoid HLA class I
presentation of endogenous self-proteins derived from proline-rich
connective tissue proteins, such as collagens, under physiological
conditions; however, pathogens or cancers may take advantage of
such a motif unfavorable for HLA presentation for their immune
escape. Therefore, this hypothesis should be further investigated.
Nevertheless, our findings in the current study could prove
beneficial for cancer immunotherapy and neoantigen/cancer-
specific Ag prediction. Although neoantigens that arise from
gene mutations are promising CTL targets in tumor immuno-
therapy, responsible gene mutations are, more often than not,
patient-specific; therefore, hundreds or thousands of somatic tumor
mutations must be surveyed for every case (36, 37). Considering
that only a very limited number of mutations are presented by
HLA and elicit T cell responses (38), accurate algorithms ac-
companied by fewer false-positive hits are in great demand. In-
tegration of the proline rule may decrease false-positive hits and
improve current prediction tools.
FIGURE 5. Ag processing in the ER fails to remove up-
stream prolines. (A) A panel of ER-IV9 constructs. Each
construct contains an ER signal sequence followed by N-terminal–
flanking residues as well as IV9 coupled with a stop codon. (B)
RT-PCR of T2-A24 cells stably expressing indicated ER-IV9 con-
structs. Shown is a representative image of three independent ex-
periments. (C) IFN-g production of the IV9-specific CTL clone
against 293T-A24 cells expressing indicated ER-IV9 constructs. (D)
IFN-g production of the CTL clone against 293T-A24 cells
expressing ER.WT in the presence or absence of 20 nM carfilzomib
or bortezomib. IFN-g spots from the ELISPOT assay are shown as
mean 6 SEM (n = 3), and p values were calculated using a two-
tailed t test. **p , 0.01.
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